Atossa Therapeutics, Inc. revenue

Atossa Therapeutics, Inc.'s revenue was $1,758 in fiscal 2015, down 95.6% on the year before. Since fiscal 2011 ($1,500) it has grown at a compound 4.0% a year. Over the last twelve months it was $1,758.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Atossa Therapeutics, Inc.: revenue history, annual
Fiscal year	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	LTMSept 2016
Revenue	2	482	633	40	2	2
Growth on the year before	—	+>999%	+31.3%	−93.7%	−95.6%	—
Gross profit	−96	416	137	40	−131	—
Gross margin	—	86.4%	21.7%	100.0%	—	—

US$ thousands unless shown otherwise. Fiscal quarters.

Atossa Therapeutics, Inc.: revenue history, quarterly
Quarter	2014 Q4Dec 2014	2015 Q1Mar 2015	2015 Q2Jun 2015	2015 Q3Sept 2015	2015 Q4Dec 2015	2016 Q1Mar 2016	2016 Q2Jun 2016	2016 Q3Sept 2016
Revenue	3	0	0	0	2	0	0	0
Growth on the same quarter a year before	—	—	—	—	−35.2%	—	—	—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Atossa Therapeutics, Inc.	$1,758	-35.2%	-86.3%
Creative Medical Technology Holdings, Inc.	$3,000	-50.0%	-65.6%
Lyell Immunopharma, Inc.	$27,000	-55.0%	-91.8%
AIM Immunotech Inc.	$95,000	-21.5%	-17.3%
Ibio, Inc.	$100,000	-75.0%	-62.4%
Lisata Therapeutics, Inc.	$100,000	-90.7%	—

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Atossa Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Atossa Therapeutics, Inc.